On April 11, no-moat Guardant presented new data on its Shield early cancer screening test, which appears likely to eventually develop into a viable multicancer test. The new data, announced during ...
Tuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's (NASDAQ:GH) experimental blood test for colorectal cancer, suggesting it might not detect some tumor types that could ...
Guardant Health says it is the first blood test approved by the FDA as a primary screening option for colorectal cancer. Shield is also the first blood test for colorectal cancer screening that meets ...
FDA approval of a Guardant Health blood test that screens for colorectal cancer makes it the first liquid biopsy approved for this type of cancer, clearing the way to make this test more accessible to ...
To screen for colon and rectal cancers, most people have colonoscopies, which can feel invasive and require anesthesia, or they may take an at-home stool test, which can be more convenient but also ...
Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
(Reuters) - Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...
Its recently approved Shield diagnostics kit made a magazine's list of top innovations for the year. The publication praised its ease of use and its effectiveness. One of the top innovations of 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback